Overview

Gender

male

Dr. Opgenorth serves part-time as Vice President of CSU Ventures, and Executive Director for NeoTREX® the enterprise arm of Colorado State University's Cancer Supercluster.

He joined CSU Ventures after retiring in 2007 from Abbott Laboratories, where he was Divisional Vice President of Metabolic Disease Research, Antiviral Research and Target-Lead Discovery Research for Abbott's Global Pharmaceutical Research and Development Division. At Abbott he championed a number of biotechnology collaborations, and led teams that advanced multiple drug candidates into clinical development.

He is also a Volwiler Fellow. Dr. Opgenorth serves as a Director on Boards of Keystone Symposia, KromaTiD, and Cetya, and serves on Scientific Advisory Boards for Keystone Symposia and Euroscreen, SA. Along with being founder and CSO of VetDC, he is acting CEO of Vidasym, Inc., a discovery company developing drugs for treatment of human chronic kidney disease.

He holds a BA in Biology from Calvin College, and MS and PhD degrees in Physiology from University of Illinois-Urbana.